Genenta Science S.p.A. (GNTA)
NASDAQ: GNTA · Real-Time Price · USD
0.857
-0.003 (-0.31%)
At close: Mar 9, 2026, 4:00 PM EDT
0.857
0.00 (0.00%)
After-hours: Mar 9, 2026, 7:20 PM EDT
Genenta Science Employees
Genenta Science had 13 employees as of December 31, 2024. The number of employees decreased by 1 or -7.14% compared to the previous year.
Employees
13
Change (1Y)
-1
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$785,995
Market Cap
20.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -1 | -7.14% |
| Dec 31, 2023 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| IO Biotech | 78 |
| Citius Pharmaceuticals | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| VYNE Therapeutics | 13 |
| Intensity Therapeutics | 7 |
| Allarity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| NanoViricides | 7 |
GNTA News
- 10 days ago - Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform - GlobeNewsWire
- 5 weeks ago - Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments - Benzinga
- 5 weeks ago - Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator - GlobeNewsWire
- 2 months ago - Genenta Science Provides Update on CEO Ownership - GlobeNewsWire
- 3 months ago - Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial - GlobeNewsWire
- 4 months ago - Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating - Seeking Alpha
- 4 months ago - Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
- 4 months ago - Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production - GlobeNewsWire